Comprehensive analysis of a new prognosis signature based on histone deacetylases in clear cell renal cell carcinoma

Histone deacetylases (HDAC) family is vital for tumorigenesis and tumor progression. However, the exact role of the HDAC family in clear cell renal cell carcinoma (ccRCC) remains unclear. Based on The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and The Human Protein Atlas (HPA) database, we investigated and validated the expression profile, clinical significance and prognostic value of HDAC family members in ccRCC. Moreover, we further explored the correlation between HDACs and tumor microenvironment, tumor stemness, drug activity and immune subtype. The HDAC8, HDAC10, and HDAC11 manifested potential clinical value for prognosis, and the correlation analyses reveals underlying molecular mechanisms, which deserve further investigation for ccRCC. This Integrated bioinformatics analysis, based on transcriptomics and proteomics, implied that HDAC8, HDAC10, and HDAC11 may serve as potential molecular biomarkers and therapeutic targets for ccRCC, but some underlying molecular mechanisms still need to be elucidated. Risk model consisting of HDAC8, HDAC10, and HDAC11 have a favorable role of risk prediction in ccRCC. Immune‐associated functions and pathways were enriched in HDACs, and most of HDACs are related to tumor stemness, stromal cell, and immune cells. Several clinical characteristics are associated with HDACs expression and the activity of some commonly used drugs (such as oxaliplatin, vorinostat, temsirolimus) are also influenced by HDACs.